A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

Breast Cancer Research and Treatment

Volumn 99, Issue 2, 2006, Pages 177-184

  McDonald, Cari J ^a   Erlichman, Charles ^a   Ingle, James N ^a   Rosales, Gabriela A ^a   Allen, Cory ^a   Greiner, Suzanne M ^a   Harvey, Mary E ^a   Zollman, Paula J ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast cancer; CEA; Measles virus; MV CEA; Virotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOGENIC EFFECT; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEASLES VIRUS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR GROWTH; VIRUS ATTENUATION; VIRUS GENE;

ANIMALS; ANTIGENS, CD46; APOPTOSIS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33747605533     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9200-5     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics. CA Cancer J Clin 55(1): 10-30, 2005
2. Wild TF, Malvoisin E, Buckland R: Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 72(Pt 2): 439-442, 1991
3. Dorig RE, Marcil A, Chopra A, Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75(2): 295-305, 1993
4. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67(10): 6025-6032, 1993
5. Tatsuo H, Ono N, Tanaka K, Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature 406(6798): 893-897, 2000
6. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M: Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36(13-14): 929-939, 1999
7. Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I: Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?. Cancer Immunol Immunother 54(2): 149-156, 2005
8. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ: Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98(7): 2002-2007, 2001
9. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ: Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62(16): 4656-4662, 2002
10. Cutts FT, Markowitz LE: Successes and failures in measles control. J Infect Dis 170(Suppl 1): S32-S41, 1994
11. Yanagi Y: [The cellular receptor for measles virus]. Uirusu 51(2): 201-208, 2001
12. Schneider U, von Messling V, Devaux P, Cattaneo R: Efficiency of measles virus entry and dissemination through different receptors. J Virol 76(15): 7460-7467, 2002
13. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ: Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8(5): 527-531, 2002
14. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103(5): 1641-1646, 2004. Epub 2003 Nov 1646. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer
15. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA: Rescue of measles viruses from cloned DNA. EMBO J 14(23): 5773-5784, 1995
16. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA: Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol 75(2): 910-920, 2001
17. Spearman C: The method of right and wrong cases without Gauss's formula. Br J Psychol 2: 227-242, 1908
18. Cathomen T, Naim HY, Cattaneo R: Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72(2): 1224-1234, 1998
19. Dethlefsen LA, Prewitt JM, Mendelsohn ML: Analysis of tumor growth curves. J Natl Cancer Inst 40(2): 389-405, 1968
20. Rencher AC: Methods of Multivariate Analysis . (nd ed.). John Wiley & Sons, New York, NY, 2002
21. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC: Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63(10): 2462-2469, 2003
22. Dummer R, Bergh J, Karlsson Y, Horowitz JA, Mulder NH, Huinink DTB, Burg G, Hofbauer G, Osanto S: Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 7(7): 1069-1076, 2000
23. Anderson BD, Nakamura T, Russell SJ, Peng KW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64(14): 4919-4926, 2004
24. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101(1): 3-27, 2004
25. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, et al Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14): 3422-3433, 2001
26. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL: Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7(5): 1237-1245, 2001
27. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ: Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23(2): 209-214, 2005. Epub 2005 Jan 2030
28. Rushmere NK, Knowlden JM, Gee JM: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108(6): 930-936, 2004. Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer
29. Oglesby TJ, White D, Tedja I, Liszewski K, Wright L, Van den Bogarde J, Atkinson JP: Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor. Trans Assoc Am Physicians 104: 164-172, 1991
30. Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP: Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 147(9): 3005-3011, 1991
31. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149(1): 129-142, 1996
32. Matsumura A, Ghosh A, Pope GS, Darbre PD: Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 94(5): 431-443, 2005
33. Boerner JL, Gibson MA, Fox EM, Posner WD, Parsons SJ, Silva CM, Shupnik MA: Estrogen negatively regulates EGF-mediated STAT5 signaling in HER family receptor overexpressing breast cancer cells. Mol Endocrinol 19(11): 2660-2670, 2005
34. Leirdal M, Shadidy M, Rosok O, Sioud M: Identification of genes differentially expressed in breast cancer cell line SKBR3: potential identification of new prognostic biomarkers. Int J Mol Med 14(2): 217-222, 2004
35. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J: Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res 11(12): 4357-4364, 2005
36. Esolen LM, Park SW, Hardwick JM, Griffin DE: Apoptosis as a cause of death in measles virus-infected cells. J Virol 69(6): 3955-3958, 1995
37. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, et al A reevaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7(8): 2357-2362, 2001